Sage Therapeutics to discontinue development of Alzheimer's drug-February 2024-www.financetom.com

Sage Therapeutics to discontinue development of Alzheimer's drug

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Sage Therapeutics to discontinue development of Alzheimer's drug

Oct 8, 2024 10:20 PM

Oct 8 (Reuters) - Sage Therapeutics ( SAGE ) said on

Tuesday it will discontinue the development of its Alzheimer's

disease drug as it did not meet the main goal in a mid-stage

trial.

Previous page： BRIEF-Webtoon Entertainment Offers 15 Million Shares Of Common Stock To Be Sold In IPO Next page： Naver's Webtoon Entertainment targets up to $2.67 bln valuation in US IPO

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

BRIEF-Webtoon Entertainment Offers 15 Million Shares Of Common Stock To Be Sold In IPO

Jun 17, 2024

June 17 (Reuters) - Naver Corp: * WEBTOON ENTERTAINMENT INC. SAYS OFFERING 15 MILLION SHARES OF COMMON STOCK TO BE SOLD IN IPO - SEC FILING * WEBTOON ENTERTAINMENT INC SAYS ESTIMATES IPO PRICE PER SHARE WILL BE BETWEEN $18.00 AND $21.00 - SEC FILING * WEBTOON ENTERTAINMENT INC. : ON JUNE 16 NAVER U.HUB INC ENTERED STOCK PURCHASE AGREEMENT...

Naver's Webtoon Entertainment targets up to $2.67 bln valuation in US IPO

Jun 17, 2024

June 17 (Reuters) - Online comics platform Webtoon Entertainment said on Monday it is targeting a valuation of up to $2.67 billion in its initial public offering in the United States. The company, majority-owned by South Korean tech giant Naver , is aiming to raise as much as $315 million by offering 15 million shares at a price range of...

Top Premarket Decliners

Jun 17, 2024

08:02 AM EDT, 06/17/2024 (MT Newswires) -- Ovid Therapeutics ( OVID ) shares slumped 64% Monday premarket after the company said that phase 3 studies conducted by Takeda evaluating Soticlestat in certain types of epilepsy missed their primary endpoints. Kaival Brands Innovations Group ( KAVL ) shares fell 35%, paring Friday's rally. La Rosa Holdings ( LRHC ) shares retreated...

Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints

Jun 17, 2024

07:59 AM EDT, 06/17/2024 (MT Newswires) -- Takeda Pharmaceutical ( TAK ) said Monday its phase 3 trials evaluating soticlestat to treat refractory Dravet syndrome and Lennox-Gastaut syndrome missed the primary endpoints. The study evaluating soticlestat in participants with Dravet syndrome narrowly missed the primary endpoint of reduction from baseline in convulsive seizure frequency compared to placebo, while the study...